Danaher Corporation $DHR Shares Bought by Lecap Asset Management Ltd.

Key Points

• Lecap Asset Management Ltd. increased its stake in Danaher Corporation by 185.2%, owning 4,073 shares valued at $805,000 as of its latest SEC filing.
• Danaher reported a quarterly EPS of $1.80, exceeding analysts' expectations of $1.64, with revenue totaling $5.94 billion, surpassing the forecast of $5.83 billion.
• The company announced a quarterly dividend of $0.32 per share, with an annualized dividend yield of 0.6%, payable on October 31st.

Lecap Asset Management Ltd. grew its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 185.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 4,073 shares of the conglomerate's stock after acquiring an additional 2,645 shares during the quarter. Lecap Asset Management Ltd.'s holdings in Danaher were worth $805,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after buying an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after buying an additional 612,154 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after buying an additional 194,466 shares during the period. Invesco Ltd. lifted its holdings in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after buying an additional 1,450,703 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Danaher by 4.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock valued at $867,168,000 after buying an additional 163,332 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Trading Down 1.1%

Shares of NYSE DHR opened at $210.64 on Friday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The business has a 50-day moving average price of $200.00 and a two-hundred day moving average price of $197.40. The firm has a market capitalization of $150.83 billion, a PE ratio of 44.82, a PEG ratio of 3.03 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period last year, the company posted $1.72 earnings per share. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio (DPR) is currently 27.23%.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.10% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on DHR shares. Evercore ISI cut their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. UBS Group cut their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Finally, Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a report on Friday, July 11th. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Danaher has a consensus rating of "Moderate Buy" and an average price target of $245.91.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.